Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glaucoma: diagnosis and management.

D A Infeld1, J G O'Shea

  • 1Glaucoma Service, Birmingham and Midland Eye Centre, UK.

Postgraduate Medical Journal
|May 13, 1999
PubMed
Summary

Glaucoma, a leading cause of blindness, affects millions globally. Early detection and community awareness are key to reducing its impact, though new treatments require further evaluation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A history of the St John Ophthalmic Hospital, Jerusalem.

Proceedings of the Royal College of Physicians of Edinburgh·2001
Same author

A survey of vernal keratoconjunctivitis and other eosinophil-mediated external eye diseases amongst Palestinians.

Ophthalmic epidemiology·2000
Same author

The St John Ophthalmic Hospital: a medical ambassador in Jerusalem.

Eye (London, England)·1999
Same author

Excimer laser ophthalmic surgery: evaluation of a new technology.

Postgraduate medical journal·1999
Same author

Age-related macular degeneration.

Postgraduate medical journal·1998
Same author

Diabetic retinopathy.

Postgraduate medical journal·1998

Area of Science:

  • Ophthalmology
  • Genetics
  • Public Health

Background:

  • Glaucoma is the third leading cause of global blindness, impacting over 5 million people.
  • Prevalence increases with age, particularly in Western countries, with primary open-angle glaucoma affecting 1.1% to 3% of the population.
  • Ethnicity, genetic factors, and hemodynamic/biochemical co-factors influence glaucoma risk and progression.

Purpose of the Study:

  • To review recent scientific advances in understanding glaucoma pathogenesis.
  • To discuss emerging topical medications and evaluate their impact and cost-effectiveness.
  • To examine differing treatment strategies, including early surgical intervention versus conservative management.

Main Methods:

  • Review of recent scientific literature on glaucoma genetics, pathogenesis, and treatment.
  • Analysis of new topical glaucoma medications and their clinical impact.
  • Comparison of various treatment modalities, including surgical and medical interventions.

Main Results:

  • Advances in understanding glaucoma include genetic mechanisms and the role of hemodynamic and biochemical factors in normal-tension glaucoma.
  • New topical medications for glaucoma have been developed, but their long-term impact and cost-effectiveness need further assessment.
  • Current treatments focus on reducing intra-ocular pressure; no definitive neuroprotective or optic nerve perfusion-influencing medications exist.

Conclusions:

  • Effective glaucoma management relies on reducing intra-ocular pressure, with ongoing research into neuroprotection and improved optic nerve perfusion.
  • Diverse treatment approaches exist, with varying opinions on the optimal timing of surgical intervention.
  • Increased community awareness and earlier detection are crucial for reducing glaucoma-related morbidity and improving patient quality of life.

Related Experiment Videos